- Previous Close
0.5680 - Open
0.5680 - Bid --
- Ask --
- Day's Range
0.5320 - 0.5700 - 52 Week Range
0.2970 - 0.9500 - Volume
110,100 - Avg. Volume
299,208 - Market Cap (intraday)
29.264M - Beta (5Y Monthly) 1.61
- PE Ratio (TTM)
-- - EPS (TTM)
-1.4400 - Earnings Date Sep 23, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Poxel S.A., a clinical-stage biopharmaceutical company, develops novel treatments for metabolic diseases, type 2 diabetes, and liver diseases. The company's lead product is TWYMEEG (Imeglimin), an oral drug candidate that targets mitochondrial dysfunction and approved for the treatment of type 2 diabetes in Japan. It also develops PXL770, an adenosine monophosphate-activated protein kinase enzyme, which is in a Phase 2a clinical trial that treats chronic metabolic diseases, including diseases that affect the liver, such as non-alcoholic steatohepatitis (NASH); PXL065, an earlier stage programs that is in Phase 2 for the treatment of NASH focusing on chronic and rare metabolic indications. The company has a licensing agreement with Enyo Pharma S.A.S. for the development of farnesoid X receptor that is in Phase 2a study for the treatment of hepatitis B and NASH; and DeuteRx LLC for the development of PXL065, a mitochondrial dysfunction; and Sumitomo Pharma for development and commercialization of Imeglimin. Poxel S.A. was incorporated in 2009 and is headquartered in Lyon, France.
www.poxelpharma.comRecent News: POXEL.PA
View MorePerformance Overview: POXEL.PA
Trailing total returns as of 9/12/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: POXEL.PA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: POXEL.PA
View MoreValuation Measures
Market Cap
29.95M
Enterprise Value
68.31M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
11.20
Price/Book (mrq)
--
Enterprise Value/Revenue
44.19
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-79.55%
Return on Equity (ttm)
--
Revenue (ttm)
1.55M
Net Income Avi to Common (ttm)
-44.24M
Diluted EPS (ttm)
-1.4400
Balance Sheet and Cash Flow
Total Cash (mrq)
7.6M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-22.73M